Replies to post #38281 on MyDx Inc. (fka MYDX)

[RadioSilent]

It seems like a good idea. My understanding is that the user will register the type of oil being used, and then the pen will register feedback from the pen (# of puffs, frequency, etc) and from the user (feelings encountered, symptoms/pain relieved, etc). With the accumulation of data user could focus in on the right brand and dosage to achieve the desired results.

To the extent that MYDX can build a proprietary feed to its database the device should be tied very strongly to MYDX. Other companies might be able to sell it, but MYDX should have the ability to control access to our data (i.e. other companies couldn't sell the same version as us, or we could charge for the data).

[Darth IxIoN]

Thanks for the link already read that one where it has me thrown is here;

On February 8, 2017, MyDx, Inc. entered into an option agreement (the “Option Agreement’) with the Torque Research & Development, Inc. ("TRD"). The Option Agreement provides MyDx with the exclusive right to license two patent pending inventions (the “TRD Inventions”), and requires MyDx to make annual payments to TRD as well as royalty payments on any products that are commercialized which are based on the TRD Inventions. MyDx's rights under the Option Agreement require customary measures of performance on the part of MyDx in terms of patent cost maintenance and other payments of costs associated with the TRD Inventions. With respect to the Option Agreement, MyDx rights are broad in terms of the potential access MyDx has to use the TRD Inventions in products, and services and many of the key economic terms of a future license, should MyDx exercise it’s rights under the Option Agreement, are agreed to in the Option Agreement.

In addition to the Option Agreement with the TRD, on February 8, 2017, MyDx has entered into a research and development agreement (the “RD Agreement”) with TRD for the Project titled “Manufacturable, Medical Grade Smart Vape Devices and Related Medical Software Applications for Prescribers, Administrators and Patient Applications.” The RD Agreement allows MyDx to fund research based on the TRD Inventions with a three year budget of $280,371 and a deferred payment of $75,000 within ninety days of the Effective Date. The RD Agreement provides MyDx with an exclusive right to license all technology that is discovered from the monies funded to TRD through the RD Agreement (the “Derivative IP”). To the extent that MyDx exercises it’s rights under the RD Agreement, MyDx will be required to make customary annual payments to TRD, who shall be the owners of any Derivative IP, as well as royalty payments as any commercialization of such Derivative IP occurs. TRD may elect to accept payment in whole or in part in cash or the companies restricted common stock priced at the Effective Date.

SOURCE: http://ir.cdxlife.com/all-sec-filings/xbrl_doc_only/993